Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00220285
Status:
COMPLETED
Last Update Posted:
2014-12-30
First Post:
2005-09-21
Brief Title:
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkins Lymphoma
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Phase II Open-label Study of SH L 749 in Relapsed or Refractory Indolent B-cell Non-Hodgkins Lymphomas
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the antitumor effect and safety of the product for relapsed or refractory indolent B-cell non-Hodgkins lymphomas
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer Schering Pharma AG GermanyBayer Schering Pharma AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 305618 | None | None | None |